The FDA has accepted for Priority Review a supplemental application for PADCEV (enfortumab vedotin) combined with Keytruda (pembrolizumab) as a perioperative treatment for muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility. This follows positive Phase 3 EV-304 trial results showing significant reduction in tumor recurrence and death risk compared to standard chemotherapy. If approved, this would be the first perioperative regimen for MIBC patients irrespective of cisplatin eligibility, potentially setting a new standard of care. The FDA aims to decide by August 17, 2026, and the data will be reviewed by other global health authorities for regulatory filings.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
